This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GALLANT 6 Tesaglitazar vs. Pioglitazone

This study has been terminated.
(The development program has been terminated)
Information provided by:
AstraZeneca Identifier:
First received: September 20, 2005
Last updated: November 17, 2010
Last verified: November 2010
This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.

Condition Intervention Phase
Diabetes Mellitus, Type 2 Drug: Galida Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)

Secondary Outcome Measures:
  • The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide
  • Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model
  • Lipid parameters
  • FPG, homeostasis assessment model, insulin, proinsulin, C-peptide
  • Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values
  • Pharmacokinetics of tesaglitazar
  • Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination
  • Assess the effects on patient-reported outcomes using the Medical Outcomes Study Short Form-36 (SF-36)
  • Validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) (US only).

Estimated Enrollment: 1450
Study Start Date: August 2004
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provision of a written informed consent
  • Men or women who are ³18 years of age
  • Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

Exclusion Criteria:

  • Type 1 diabetes
  • New York Heart Association heart failure Class III or IV
  • Treatment with chronic insulin
  • History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the upper limit of normal
  • Received any investigational product in other clinical studies within 12 weeks
  • Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00214565

  Hide Study Locations
United States, Pennsylvania
Research Site
Altoona, Pennsylvania, United States
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Moron- Buenos Aires, Argentina
Research Sites
Quilmes - Buenos Aires, Argentina
Research Site
Rosario, Argentina
Research Site
Salta, Argentina
Research Site
Curitiba, Brazil
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Abbotsford, British Columbia, Canada
Research Site
Chilliwack, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Canada, Nova Scotia
Research Site
Dartmouth, Nova Scotia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Truro, Nova Scotia, Canada
Research Site
Windsor, Nova Scotia, Canada
Canada, Ontario
Research Site
Brampton, Ontario, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Niagara Falls, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Scarborough, Ontario, Canada
Research Site
St. Catharines, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Windsor, Ontario, Canada
Canada, Quebec
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Chicoutimi, Canada
Research Site
Longueuil, Canada
Research Site
Montreal, Canada
Research Site
St. John's, Canada
Research Site
Espoo, Finland
Research Site
Helsinki, Finland
Research Site
Kuopio, Finland
Research Site
Pietarsaar, Finland
Research Site
Pori, Finland
Research Site
Tampere, Finland
Research Site
Guadalajara Jalisco, Mexico
Research Site
Mexico City, Mexico
Research Site
Mexico, Mexico
Research Site
Nuevo Leon, Mexico
Research Site
Puebla, Mexico
Research Site
Torreon, Mexico
Research Site
Zapopan, Mexico
Research Site
Bergen, Norway
Research Site
Elvernum, Norway
Research Site
Hamar, Norway
Research Site
Horten, Norway
Research Site
Kongsberg, Norway
Research Site
Lena, Norway
Research Site
Loeten, Norway
Research Site
Lysaker, Norway
Research Site
Oslo, Norway
Research Site
Osteraas, Norway
Research Site
Skedsmokorset, Norway
Research Site
Straume, Norway
Research Site
Toensberg, Norway
Research Site
Tronheim, Norway
Research Site
Ås, Norway
United Kingdom
Research Site
Dublin, Ireland, United Kingdom
Research Site
Wexford, Ireland, United Kingdom
Research Site
Antrim, NI, United Kingdom
Research Site
Belfast, United Kingdom
Research Site
Cardiff, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Kent, United Kingdom
Research Site
Leeds, United Kingdom
Research Site
Mid Glamorgan, United Kingdom
Research Site
Pembrokeshire, United Kingdom
Research Site
Plymouth, United Kingdom
Research SIte
Reading, United Kingdom
Research Site
Surrey, United Kingdom
Research Site
Wiltshire, United Kingdom
Sponsors and Collaborators
Study Director: AstraZeneca Galida Medical Science Director, MD AstraZeneca
  More Information Identifier: NCT00214565     History of Changes
Other Study ID Numbers: D6160C00030
Study First Received: September 20, 2005
Last Updated: November 17, 2010

Keywords provided by AstraZeneca:
Type 2 diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 20, 2017